Fulgent Genetics (FLGT) Receivables (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Receivables data on file, last reported at $69.3 million in Q1 2026.

• Quarterly Receivables fell 6.4% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (down 6.4% YoY) and the FY2025 annual result came in at $85.9 million, up 21.34% from the prior year.
• Receivables retreated to $69.3 million in Q1 2026 per FLGT's latest filing, from $85.9 million in the prior quarter.
• The five-year high for Receivables was $161.8 million in Q1 2022, with the low at $1.1 million in Q3 2023.
• Average Receivables over 5 years is $72.0 million, with a median of $70.8 million recorded in 2024.
• Year-over-year, Receivables sank 98.92% in 2023 and soared 5093.71% in 2024.
• Fulgent Genetics' Receivables stood at $72.6 million in 2022, then declined by 27.74% to $52.5 million in 2023, then surged by 34.96% to $70.8 million in 2024, then climbed by 21.34% to $85.9 million in 2025, then slipped by 19.35% to $69.3 million in 2026.
• Business Quant data shows FLGT's Receivables at $69.3 million in Q1 2026, $85.9 million in Q4 2025, and $72.6 million in Q3 2025.